Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1836 - Clinical and Psychometric validation of the BreSAS Questionnaire for Symptom Assessment among Breast Cancer Survivors.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Survivorship

Tumour Site

Breast Cancer

Presenters

Raffaele Giusti

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

R. Giusti1, E. Scarpi2, K. Cannita3, R.R. Silva4, M. Filetti1, M. Mazzotta1, R. Rossi5, V. Cocciolone3, T. Sidoni3, M. Tudini4, C. Ficorella3, A. Botticelli6, P. Marchetti1, G. Porzio3, L. Verna3

Author affiliations

  • 1 Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant' Andrea, 00189 - Rome/IT
  • 2 Biostatistics And Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC)/IT
  • 3 Medical Oncology Unit, S. Salvatore Hospital, University of L'Aquila, 67100 - L'Aquila/IT
  • 4 Medical Oncology Unit, Ospedale E. Profili U.O. Oncologia Medica, 60044 - Fabriano/IT
  • 5 Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 - Meldola (FC)/IT
  • 6 Medical Oncology Unit, Azienda Ospedaliera St. Andrea, 00189 - Roma/IT
More

Resources

Abstract 1836

Background

Today a large number of breast cancer (BC) patients survive many years post diagnosis. The large number of women surviving many years post BC diagnosis has heightened interest in studying long-term effects of cancer on quality of life. A number of cancer-specific health-related quality of life (QoL) measures have been developed but these measures may not be appropriate for use with long-term survivors. With this study we want to evaluate the reliability, clinical and psychometric validity of the BreSAS Questionnaire (BQ) among BC survivors.

Methods

The BQ is a quick, simple 10 items module for the assessment of long-term physical, psychological, sexual and cognitive effects that may influence quality of life (pain, anxiety, depression, fatigue, irritability, quality of sleep, impaired concentration, hot flashes, vaginal itching, other). The total BreSAS score ranks from 0-100, with a low score indicating a better QoL. Patients were not stratified into predetermined clinically distinct groups. QoL data were collected alongside standard outcomes in patients undergoing treatment for BC. Patients complete the BQ, the FACT-ES questionnaire, case report forms for clinical and socio-demographic data at different time points during follow up visits. Reliability, and clinical and psychometric validity of the questionnaires are assessed by correlation analyses, exploration of known group comparisons, and responsiveness to clinical changes.

Results

From September 2015 to February 2016, 149 patients from three Italian oncology units were enrolled. Baseline questionnaires were returned from all and the majority of patients (n = 134 - 89%) completed the BQ and FACT-ES in less than 15 min. For reliability, Cronbach’s alpha coefficients for each scale were greater than 0.70 in all analyzed symptoms. Convergent validity of BQ showed by Pearson’s r demonstrated a high correlation between intensity of symptoms and QoL, especially for pain and depression. No data were provided about reproducibility with test-retest study.

Conclusions

The BQ demonstrates sufficient validity and reliability to support its use to assess patient-reported outcomes and symptom assessment during planned follow-up clinical visits among BC survivors.

Clinical trial identification

Legal entity responsible for the study

Giampiero Porzio.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.